Sigilon Therapeutics Inc
NASDAQ:SGTX
Earnings Announcements
Sigilon Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results And Business Highlights
Published: 03/18/2021 21:31 GMT
Sigilon Therapeutics Inc (SGTX) - Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights.
Sigilon Therapeutics, Inc. - Qtrly Loss per Share $1.15.
Sigilon Therapeutics, Inc. - Cash Was $202.2 Million As of December 31, 2020.
Sigilon Therapeutics, Inc. - Qtrly Loss per Share $1.15.
Sigilon Therapeutics, Inc. - Cash Was $202.2 Million As of December 31, 2020.
Revenue is expected to be $2.95 Million
Adjusted EPS is expected to be -$0.66
Next Quarter Revenue Guidance is expected to be $2.95 Million
Next Quarter EPS Guidance is expected to be -$0.64
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.66
Next Quarter Revenue Guidance is expected to be $2.95 Million
Next Quarter EPS Guidance is expected to be -$0.64
More details on our Analysts Page.